Scholarlink

<p>Progress in cancer therapy has been driven by biological nanotechnology, which utilizes functional nanoplatforms to enhance treatment outcomes. Zeolitic imidazolate frameworks (ZIFs), which are metal-organic frameworks (MOFs), have gained attention in cancer treatment and are valued for their protective properties, structural flexibility, resistance to chemical and thermal variations, and potential for functional modification. Additionally, developing drug delivery systems that are sensitive to pH variations is crucial for achieving effective cancer therapy. In this study, a novel ZIF-67-based drug carrier was designed for pH-responsive targeted delivery of curcumin (CUR). Additionally, hyaluronic acid (HA) was applied as a coating over the CUR-encapsulated ZIF-67 to form HA-coated CUR@ZIF-67. These compounds were characterized using UV-visible (UV-Vis) and Fourier Transform Infrared (FTIR) spectroscopy, X-ray diffraction (XRD), Brunauer-Emmett-Teller (BET) adsorption-desorption isotherms, zeta potential analysis, dynamic light scattering (DLS) analysis, transmission and scanning electron microscopy (TEM &amp; SEM) and thermogravimetric analysis (TGA). The drug-loading efficiency was high, and the carrier demonstrated substantial chemical stability. In vitro studies revealed a controlled drug release of 87.7% over 120&#xa0;h under acidic conditions. HA-coated CUR@ZIF-67 exhibited reduced drug leaching under physiological conditions compared with uncoated CUR@ZIF-67. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay conducted on human epithelial liver (HepG-2) cells indicated that HA-coated CUR@ZIF-67 achieved 87.8% cytotoxicity, likely owing to HA’s interaction with CD-44 receptors, thereby facilitating targeted delivery.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hyaluronic Acid-Coated Zeolitic Imidazolate Framework (ZIF-67) for the Targeted and pH-Responsive Drug Delivery System

  • 期刊论文

  • 发表日期：

    2025年11月28日

查看全文
  • K. Bijudas,
  • S. Megha,
  • G. Greeshma,
  • R. Reshma,
  • K. R. Jiju

摘要

Progress in cancer therapy has been driven by biological nanotechnology, which utilizes functional nanoplatforms to enhance treatment outcomes. Zeolitic imidazolate frameworks (ZIFs), which are metal-organic frameworks (MOFs), have gained attention in cancer treatment and are valued for their protective properties, structural flexibility, resistance to chemical and thermal variations, and potential for functional modification. Additionally, developing drug delivery systems that are sensitive to pH variations is crucial for achieving effective cancer therapy. In this study, a novel ZIF-67-based drug carrier was designed for pH-responsive targeted delivery of curcumin (CUR). Additionally, hyaluronic acid (HA) was applied as a coating over the CUR-encapsulated ZIF-67 to form HA-coated CUR@ZIF-67. These compounds were characterized using UV-visible (UV-Vis) and Fourier Transform Infrared (FTIR) spectroscopy, X-ray diffraction (XRD), Brunauer-Emmett-Teller (BET) adsorption-desorption isotherms, zeta potential analysis, dynamic light scattering (DLS) analysis, transmission and scanning electron microscopy (TEM & SEM) and thermogravimetric analysis (TGA). The drug-loading efficiency was high, and the carrier demonstrated substantial chemical stability. In vitro studies revealed a controlled drug release of 87.7% over 120 h under acidic conditions. HA-coated CUR@ZIF-67 exhibited reduced drug leaching under physiological conditions compared with uncoated CUR@ZIF-67. A 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay conducted on human epithelial liver (HepG-2) cells indicated that HA-coated CUR@ZIF-67 achieved 87.8% cytotoxicity, likely owing to HA’s interaction with CD-44 receptors, thereby facilitating targeted delivery.

Graphical Abstract